(CercleFinance.com) – Theradiag posted revenue of €12.2 million for 2022, an increase of 9.7% in line with its business plan, with an increased share achieved abroad (55% compared to 52% in 2021).
The company specifies that its Theranostics activity once again shows solid growth in 2022 (+10.1%), despite fewer instruments sold, as does its historical in vitro diagnostics activity (+9.2%). despite the cessation of Covid testing activity in 2021.
‘Driven by its new strategic plan, the company will continue to improve its performance indicators in the coming semesters’, concludes Pierre Morgon, Chairman of Theradiag’s Board of Directors.